EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

ERO1α as a Potential Drug Target for Breast Cancer: A Systematic Review of Current Evidence

Kamilla Khojayeva iD, Aiman Moldasheva, Mohamad Aljofan

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262110276 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kamilla Khojayeva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, School of Medicine Nazarbayev University, Astana 010000, Kazakhstan. Hauptthemen laut MEDLINE: Breast Neoplasms, Oxidoreductases, Membrane Glycoproteins, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nazarbayev University, Nazarbayev University Collaborative Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia, oxidative stress, and impaired protein folding contribute to tumor progression and therapy resistance. Endoplasmic Reticulum Oxidoreductin 1 Alpha (ERO1α) is a key enzyme regulating redox homeostasis in the endoplasmic reticulum by reoxidizing protein disulfide isomerase, facilitating disulfide bond formation, and generating reactive oxygen species. Elevated ERO1α levels are associated with increased tumor aggressiveness, metastasis, and poor clinical outcomes. Despite growing evidence of its tumor-promoting functions, no clinically approved ERO1α inhibitors exist. This systematic review provides a comprehensive and integrative analysis of current research on ERO1α in breast cancer, emphasizing its roles in hypoxia response, angiogenesis, immune modulation, and ferroptosis resistance. We discuss mechanistic links, including VEGF-A maturation and PD-L1-mediated immune evasion, and highlight recent advances in small-molecule ERO1α inhibitors and preclinical therapeutic strategies. By consolidating molecular insights and translational considerations, this review underscores ERO1α as both a promising therapeutic target and potential prognostic marker, offering guidance for future drug development and targeted interventions in redox-dependent cancer pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsOxidoreductasesMembrane GlycoproteinsAntineoplastic AgentsHumansFemaleAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

ERO1αbreast cancerdrug targetoxidative stress

Substanzen

ERO1A protein, humanOxidoreductasesMembrane GlycoproteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences, School of Medicine Nazarbayev University, Astana 010000, Kazakhstan.
  • Drug Discovery and Development, Center of Life Sciences, National Laboratory, Astana 010000, Kazakhstan.

ORCID-Profile: Kamilla Khojayeva

Förderung

  • Nazarbayev University
  • Nazarbayev University Collaborative Research

Zitieren

APA

Khojayeva, K., Moldasheva, A., & Aljofan, M. (2025). ERO1α as a Potential Drug Target for Breast Cancer: A Systematic Review of Current Evidence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110276

Vancouver

Khojayeva K, Moldasheva A, Aljofan M. ERO1α as a Potential Drug Target for Breast Cancer: A Systematic Review of Current Evidence. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110276

BibTeX
@article{Khojayeva2025,
  author = {Khojayeva, Kamilla and Moldasheva, Aiman and Aljofan, Mohamad},
  title = {ERO1α as a Potential Drug Target for Breast Cancer: A Systematic Review of Current Evidence},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262110276}
}
Kostenlos starten →